Hypertension at an Inflection Point

Hypertension management is at an inflection point. Over the past 4 years, landmark trials have definitively established that intensive blood pressure (BP) lowering to systolic targets below 120 mm Hg reduces cardiovascular events and mortality across diverse high-risk populations, and the 2025 American Heart Association/American College of Cardiology (AHA/ACC) hypertension guideline has incorporated these findings into a universal <130/80 mm Hg goal with encouragement to achieve systolic BP <120 mm Hg when feasible. At the same time, novel pharmacological and device-based therapies have engaged mechanistic pathways previously left unopposed-endothelin, aldosterone biosynthesis, hepatic angiotensinogen, and renal sympathetic nerves-ending a >15-year drought in new antihypertensive mechanisms. This review synthesizes these converging developments and frames them within an emerging phenotype-driven framework that matches therapy to the dominant driver of uncontrolled or difficult-to-treat hypertension. The implications for cardiovascular disease prevention are substantial: more aggressive targets are now achievable through more precise therapies, and the coming years will require a shift from 1-size-fits-all stepped care toward individualized precision management.